Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Nonalcoholic steatohepatitis (NASH) is common, may progress to cirrhosis and is predicted to
become a leading indication for liver transplantation in the near future. Though often
associated with obesity and the metabolic syndrome, our current understanding of disease
development is limited and there are few therapeutic options. Imbalance of gut bacteria is
suspected to play a key role driving the progression of fatty liver disease and there is hope
manipulation of these bacteria may be beneficial. This study will determine if fecal
microbiota transplantation, using stool from lean donors, is an effective and safe treatment
for NASH.